Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05819398




Registration number
NCT05819398
Ethics application status
Date submitted
6/04/2023
Date registered
19/04/2023
Date last updated
21/11/2024

Titles & IDs
Public title
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Scientific title
Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1.
Secondary ID [1] 0 0
2022-501074-19-00
Secondary ID [2] 0 0
1368-0098
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hidradenitis Suppurativa 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Spesolimab Formulation 1
Treatment: Drugs - Spesolimab Formulation 2
Treatment: Drugs - Placebo matching Spesolimab Formulation 1
Treatment: Drugs - Placebo matching Spesolimab Formulation 2

Experimental: Part I: Low dose group -

Experimental: Part I: Medium dose group -

Experimental: Part I: High dose group -

Placebo comparator: Part I: Placebo group -

Experimental: Part II: Active (treatment) group -

Placebo comparator: Part II: Placebo group -


Treatment: Drugs: Spesolimab Formulation 1
Spesolimab Formulation 1

Treatment: Drugs: Spesolimab Formulation 2
Spesolimab Formulation 2

Treatment: Drugs: Placebo matching Spesolimab Formulation 1
Placebo matching Spesolimab Formulation 1

Treatment: Drugs: Placebo matching Spesolimab Formulation 2
Placebo matching Spesolimab Formulation 2
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Percent change from baseline in Draining fistula/tunnel (dT) count at Week 8
Timepoint [1] 0 0
At baseline and at week 8
Secondary outcome [1] 0 0
Part 1: Percent change from baseline in dT count at Week 16 (part 1)
Timepoint [1] 0 0
At baseline and at week 16
Secondary outcome [2] 0 0
Part 1: Absolute change from baseline in International hidradenitis suppurativa severity score system (IHS4) value at Week 8
Timepoint [2] 0 0
At baseline and at week 8
Secondary outcome [3] 0 0
Part 1: Absolute change from baseline in IHS4 value at Week 16
Timepoint [3] 0 0
At baseline and at week 16
Secondary outcome [4] 0 0
Part 1: Occurrence of treatment emergent adverse events (TEAEs)
Timepoint [4] 0 0
up to 64 weeks

Eligibility
Key inclusion criteria
1. Of full age of consent at screening.
2. Signed and dated written informed consent in accordance with International Council on Harmonisation-Good clinical practice (ICH-GCP) and local legislation prior to admission to the trial.
3. Moderate to severe HS.
4. HS lesions in at least 2 distinct anatomic areas.
5. Biologic naive or Tumor Necrosis Factor inhibitor (TNFi)-exposed for HS.
6. For biologic naïve, inadequate response to an adequate course of appropriate oral antibiotics for treatment of HS in the last 1 year prior to the Baseline visit, as per investigator discretion. All participants must have previous exposure to antibiotics for HS.
7. Total AN count of greater than or equal to 5.
8. Total dT count of at least 1 at Baseline visit. Further inclusion criteria apply.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
2. Prior exposure to any immunosuppressive/immunomodulatory biologic other than TNFi for HS.
3. Prior exposure to Interleukin 36 receptor (IL-36R) inhibitors including spesolimab.
4. Treated with any investigational device or investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug, whichever is longer.
5. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
6. Participants with history of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.
7. Participants with a transplanted organ (with exception of a corneal transplant >12 weeks prior to screening) or who has ever received stem cell therapy (e.g., Remestemcel-L).
8. Participants with any documented active or suspected malignancy or history of malignancy within 5 years prior to the screening visit, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.

Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/04/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/08/2028
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Holdsworth House Medical Practice - Sydney
Recruitment hospital [2] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Argentina
State/province [17] 0 0
Caba
Country [18] 0 0
Argentina
State/province [18] 0 0
Capital Federal
Country [19] 0 0
Argentina
State/province [19] 0 0
Mar del Plata
Country [20] 0 0
Argentina
State/province [20] 0 0
Rosario
Country [21] 0 0
Austria
State/province [21] 0 0
Wien
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Pleven
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Chile
State/province [25] 0 0
Comuna De Recoleta
Country [26] 0 0
Chile
State/province [26] 0 0
Vitacura
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
Changchun
Country [29] 0 0
China
State/province [29] 0 0
Changsha
Country [30] 0 0
China
State/province [30] 0 0
Chengdu
Country [31] 0 0
China
State/province [31] 0 0
Guangzhou
Country [32] 0 0
China
State/province [32] 0 0
Hangzhou
Country [33] 0 0
China
State/province [33] 0 0
Urumqi
Country [34] 0 0
China
State/province [34] 0 0
Wuhan
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha
Country [36] 0 0
Denmark
State/province [36] 0 0
København NV
Country [37] 0 0
Finland
State/province [37] 0 0
Tampere
Country [38] 0 0
France
State/province [38] 0 0
Antony
Country [39] 0 0
France
State/province [39] 0 0
Lyon
Country [40] 0 0
France
State/province [40] 0 0
Marseille
Country [41] 0 0
France
State/province [41] 0 0
Nice
Country [42] 0 0
France
State/province [42] 0 0
Paris
Country [43] 0 0
Germany
State/province [43] 0 0
Bad Bentheim
Country [44] 0 0
Germany
State/province [44] 0 0
Bochum
Country [45] 0 0
Germany
State/province [45] 0 0
Göttingen
Country [46] 0 0
Germany
State/province [46] 0 0
Merzig
Country [47] 0 0
Germany
State/province [47] 0 0
Oldenburg
Country [48] 0 0
Greece
State/province [48] 0 0
Athens
Country [49] 0 0
Israel
State/province [49] 0 0
Afula
Country [50] 0 0
Israel
State/province [50] 0 0
Petach Tikva
Country [51] 0 0
Israel
State/province [51] 0 0
Tel Aviv
Country [52] 0 0
Italy
State/province [52] 0 0
Napoli
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Japan
State/province [54] 0 0
Aichi, Nagoya
Country [55] 0 0
Japan
State/province [55] 0 0
Aichi, Toyoake
Country [56] 0 0
Japan
State/province [56] 0 0
Fukuoka, Kurume
Country [57] 0 0
Japan
State/province [57] 0 0
Gifu, Ogaki
Country [58] 0 0
Japan
State/province [58] 0 0
Okayama, Okayama
Country [59] 0 0
Japan
State/province [59] 0 0
Okinawa, Nakagami-gun
Country [60] 0 0
Japan
State/province [60] 0 0
Shiga, Otsu
Country [61] 0 0
Japan
State/province [61] 0 0
Tochigi, Shimotsuga-gun
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo, Bunkyo-ku
Country [63] 0 0
Japan
State/province [63] 0 0
Tokyo, Itabashi-ku
Country [64] 0 0
Japan
State/province [64] 0 0
Tokyo, Shinjuku-ku
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Seoul
Country [66] 0 0
Lithuania
State/province [66] 0 0
Kaunas
Country [67] 0 0
Lithuania
State/province [67] 0 0
Vilnius
Country [68] 0 0
Malaysia
State/province [68] 0 0
Georgetown Pulau Pinang
Country [69] 0 0
Malaysia
State/province [69] 0 0
Johor Bahru
Country [70] 0 0
Malaysia
State/province [70] 0 0
Kota Bahru
Country [71] 0 0
Malaysia
State/province [71] 0 0
Kuala Lumpur
Country [72] 0 0
Malaysia
State/province [72] 0 0
Kuching
Country [73] 0 0
Malaysia
State/province [73] 0 0
Selangor Darul Ehsan
Country [74] 0 0
Mexico
State/province [74] 0 0
Aguascalientes
Country [75] 0 0
Mexico
State/province [75] 0 0
Guadalajara
Country [76] 0 0
Mexico
State/province [76] 0 0
Monterrey
Country [77] 0 0
Mexico
State/province [77] 0 0
Veracruz
Country [78] 0 0
New Zealand
State/province [78] 0 0
Hamilton
Country [79] 0 0
Norway
State/province [79] 0 0
Stavanger
Country [80] 0 0
Philippines
State/province [80] 0 0
Davao City
Country [81] 0 0
Philippines
State/province [81] 0 0
Manila, Philippines
Country [82] 0 0
Philippines
State/province [82] 0 0
Quezon City
Country [83] 0 0
Poland
State/province [83] 0 0
Ossy
Country [84] 0 0
Poland
State/province [84] 0 0
Poznan
Country [85] 0 0
Poland
State/province [85] 0 0
Warsaw
Country [86] 0 0
Poland
State/province [86] 0 0
Warszawa
Country [87] 0 0
Poland
State/province [87] 0 0
Wroclaw
Country [88] 0 0
Portugal
State/province [88] 0 0
Braga
Country [89] 0 0
Portugal
State/province [89] 0 0
Lisboa
Country [90] 0 0
Portugal
State/province [90] 0 0
Porto
Country [91] 0 0
Singapore
State/province [91] 0 0
Singapore
Country [92] 0 0
Slovakia
State/province [92] 0 0
Svidnik
Country [93] 0 0
Slovakia
State/province [93] 0 0
Trnava
Country [94] 0 0
South Africa
State/province [94] 0 0
Cape Town
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Córdoba
Country [97] 0 0
Spain
State/province [97] 0 0
Granada
Country [98] 0 0
Spain
State/province [98] 0 0
Granollers
Country [99] 0 0
Spain
State/province [99] 0 0
Madrid
Country [100] 0 0
Spain
State/province [100] 0 0
Manises
Country [101] 0 0
Spain
State/province [101] 0 0
Zaragoza
Country [102] 0 0
Switzerland
State/province [102] 0 0
Basel
Country [103] 0 0
Switzerland
State/province [103] 0 0
Bern
Country [104] 0 0
Switzerland
State/province [104] 0 0
Geneve
Country [105] 0 0
Switzerland
State/province [105] 0 0
Zürich
Country [106] 0 0
Taiwan
State/province [106] 0 0
TaoYuan
Country [107] 0 0
Turkey
State/province [107] 0 0
Ankara
Country [108] 0 0
Turkey
State/province [108] 0 0
Antalya
Country [109] 0 0
Turkey
State/province [109] 0 0
Samsun
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Gloucester
Country [111] 0 0
United Kingdom
State/province [111] 0 0
London
Country [112] 0 0
Vietnam
State/province [112] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part.

This study has 2 parts. In Part 1, participants are divided into 4 groups of almost equal size. 3 groups get different doses of spesolimab, 1 group gets placebo. All participants get injections into a vein or under the skin. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has an equal chance of being in each group. In the beginning, participants get the study medicine every week and later every 2 weeks. After 4 months, participants in the placebo group switch to spesolimab treatment.

In Part 2, participants are divided into 2 groups. One group gets a suitable dose of spesolimab that was found in Part 1 of the study. The other group gets placebo. After 4 months, participants in the placebo group switch to spesolimab treatment.

Participants join only one of the two parts. They are in the study for about 1 year. During this time, they visit the study site in the beginning every week and later every 2 weeks. Some of the visits can be done at the participant's home instead of the study site. The doctors regularly check participants' HS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.
Trial website
https://clinicaltrials.gov/study/NCT05819398
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Boehringer Ingelheim
Address 0 0
Country 0 0
Phone 0 0
1-800-243-0127
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05819398